Inozyme Pharma Inc (INZY) Stock Price, Quote & News

Company Profile

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of t...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 330 4340

Website: www.inozyme.com

Address:

321 Summer Street, Suite 400, Boston, United States

SanKish Jun. 8 at 5:23 PM

$INZY did anyone receive an email for voluntary sale of your shares? I got a message from Tobinhood with a pdf attached which was signed by both Innozyme and Biomarin representatives. I thought that the money will get deposited in my account automatically after the merger is completed.

0 · Reply

NNTrader Jun. 4 at 2:02 PM

$INZY sold my shares

0 · Reply

biostock Jun. 2 at 3:46 PM

$INZY Bidding war coming? $XBI $SPY $QQQ https://www.sec.gov/Archives/edgar/data/1693011/000119312525132769/d908188dsc14d9.htm#tx908188_7

1 · Reply

movnup May. 30 at 1:12 PM

$CRBU Took some $INZY profits and bought some $CRBU.

0 · Reply

jdlman May. 30 at 4:28 AM

$INZY nice run here

0 · Reply

Paraboljoker May. 22 at 3:11 PM

$LPCN New product launch🏎️ https://x.com/uscorpfilings/status/1925548482070196613?s=46 $INZY $IXHL $EDBL $RGC

2 · Reply

YouVSYou May. 22 at 12:07 AM

$VIGL $RGLS $INZY Buyout season continues $XBI Who’s Next? https://x.com/justinss55/status/1925341843719381091?s=46

3 · Reply

BarrelOfDreams May. 21 at 8:50 PM

$LPCN $INZY $IXHL $EDBL $RGC Come take a look

0 · Reply

SpartanVI May. 21 at 7:41 PM

$LPCN $INZY $IXHL $EDBL $RGC Interesting

1 · Reply

Paraboljoker May. 21 at 7:35 PM

$LPCN Swingplay , accumulation $3.50 – $3.70 watching for updates & momentum post-event Presentation 🗓️ May 21 @ 4:00 PM at A.G.P.'s Annual Healthcare Company Showcase. 🗞️Annual Stockholder Meeting: June 4 Nearterm catalysts: Phase results, partnership news, or feedback from the FDA Pipeline Highlights - LPCN 1154 – Phase 3 initiated (Q2 2025) for postpartum depression - LPCN 1148 – Completed Phase 2 for cirrhosis-related sarcopenia (FDA Grants Fast Track Designation) - LPCN 2401 – Completed Phase 2 for obesity/lean mass improvement Bio Theme been hot lately: $INZY $IXHL $EDBL $RGC

1 · Reply

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

BMRN

May 16, 2025, 7:30 AM EDT - 4 weeks ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

BMRN

May 14, 2025, 7:30 AM EDT - 4 weeks ago

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

Apr 10, 2025, 8:30 AM EDT - 2 months ago

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Mar 31, 2025, 8:30 AM EDT - 2 months ago

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 10, 2025, 8:30 AM EDT - 3 months ago

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Feb 24, 2025, 8:30 AM EST - 4 months ago

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb 21, 2025, 8:30 AM EST - 4 months ago

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Nov 27, 2024, 8:30 AM EST - 7 months ago

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 11, 2024, 8:30 AM EST - 7 months ago

Inozyme Pharma to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:30 AM EST - 8 months ago

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Oct 24, 2024, 1:15 PM EDT - 8 months ago

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Oct 17, 2024, 8:30 AM EDT - 8 months ago

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Oct 7, 2024, 8:30 AM EDT - 9 months ago

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Sep 12, 2024, 2:35 PM EDT - 9 months ago

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

Aug 29, 2024, 8:30 AM EDT - 10 months ago

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Jul 30, 2024, 1:56 PM EDT - 11 months ago

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Jul 25, 2024, 8:30 AM EDT - 11 months ago

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Jun 21, 2024, 1:00 PM EDT - 1 year ago

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)

May 23, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

May 8, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 3, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 8, 2024, 6:30 AM EDT - 1 year ago

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Mar 8, 2024, 2:45 PM EST - 1 year ago

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Feb 26, 2024, 8:30 AM EST - 1 year ago

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Nov 27, 2023, 7:30 AM EST - 1 year ago

Inozyme: A Major Catalyst Is Uncomfortably Far Off

Nov 9, 2023, 8:30 AM EST - 1 year ago

Inozyme Pharma to Participate in Upcoming Investor Conferences

Nov 7, 2023, 8:30 AM EST - 1 year ago

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Oct 10, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions

Oct 6, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Sep 20, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

Jul 27, 2023, 11:20 PM EDT - 2 years ago

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

Jul 27, 2023, 4:33 PM EDT - 2 years ago

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

Jul 26, 2023, 7:30 AM EDT - 2 years ago

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Jul 19, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Inozyme Pharma to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Apr 14, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

SanKish Jun. 8 at 5:23 PM

0 · Reply

NNTrader Jun. 4 at 2:02 PM

$INZY sold my shares

0 · Reply

biostock Jun. 2 at 3:46 PM

$INZY Bidding war coming? $XBI $SPY $QQQ https://www.sec.gov/Archives/edgar/data/1693011/000119312525132769/d908188dsc14d9.htm#tx908188_7

1 · Reply

movnup May. 30 at 1:12 PM

$CRBU Took some $INZY profits and bought some $CRBU.

0 · Reply

jdlman May. 30 at 4:28 AM

$INZY nice run here

0 · Reply

Paraboljoker May. 22 at 3:11 PM

$LPCN New product launch🏎️ https://x.com/uscorpfilings/status/1925548482070196613?s=46 $INZY $IXHL $EDBL $RGC

2 · Reply

YouVSYou May. 22 at 12:07 AM

$VIGL $RGLS $INZY Buyout season continues $XBI Who’s Next? https://x.com/justinss55/status/1925341843719381091?s=46

3 · Reply

BarrelOfDreams May. 21 at 8:50 PM

$LPCN $INZY $IXHL $EDBL $RGC Come take a look

0 · Reply

SpartanVI May. 21 at 7:41 PM

$LPCN $INZY $IXHL $EDBL $RGC Interesting

1 · Reply

Paraboljoker May. 21 at 7:35 PM

1 · Reply

ATNews May. 21 at 2:53 PM

$DEVS $IXHL $SYTA $INZY Read this if you want to make money with us!

0 · Reply

SissyBoy May. 20 at 1:56 PM

$BMRN ripping off $INZY and they know it .

0 · Reply

SissyBoy May. 20 at 1:53 PM

$INZY - If the deal unravels, the stock could rebound toward its historical highs, especially if INZ-701’s value is unlocked. We want a bidding war!!!!

0 · Reply

BioRich May. 19 at 11:01 PM

$ALT On a positive note, when ALT takes a dump on underwhelming data at the end of June, it will only go down ~33% rather than ~60% I was expected. The benefits of having share price slide during data drought. Today's red day after Pumping they initiated AUD should be just about all you need to know about ALT's future. Glad I blocked so many pumpers. Saves me from seeing low comprehension folks trying to solve complex problems. It's a real downer. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That how we learn and find gems like some of my recent winners like $GUTS, $INZY, $SYTA and a few others. Let's make some (more) money. Cheers! $XBI

2 · Reply

ZacksResearch May. 19 at 8:09 PM

$BMRN makes a bold move with $INZY acquisition! 💥 BioMarin's $270M buyout of Inozyme Pharma aims to bring INZ-701, a pivotal enzyme therapy for rare genetic disorder, ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency, into its pipeline. Interim data in 2026 could lead to a first-in-disease approval by 2027. The acquisition is anticipated to diversify BioMarin's portfolio and eventually boost its enzyme therapies lineup. 🚀 Discover how this strategic deal benefits both companies 👉 https://www.zacks.com/commentary/2473984/biomarin-offers-to-buy-inozyme-for-270m-to-boost-enzyme-therapy-biz?cid=sm-stocktwits-2-2473984-body&ADID=SYND_STOCKTWITS_TWEET_2_2473984_BOD

2 · Reply

theflynews May. 19 at 3:00 PM

Biotech Alert: Searches spiking for these stocks today - $INZY - https://thefly.com/permalinks/entry.php/INZYid4132869?1747666354C38

1 · Reply

QCashMoney May. 19 at 2:50 PM

$INZY cannot go lower than $4 due to being acquired at $4, but is there actual potential that a lawsuit could bring that offer price higher? since apparently it is being sold at an unreasonably low price

0 · Reply

HopefulCass May. 19 at 2:12 PM

$INZY can someone help. What do i do now? Do i sell? Do people wait? Why would anyone wait?

3 · Reply

SPrinTR_PipGunk May. 19 at 1:49 PM

$INZY Spotted this one early thanks to an alert📊🍔 - noticed the pre-market volume and social chatter picking up, the setup looked solid… and sure enough, it took off🔥 Been trying out the app for a bit - it tracks real-time buzz from Reddit, Twitter, and Discord, filters out the noise, and highlights tickers that are truly gaining traction. A few of the alerts have popped off well before the scanners even caught on. If you’re into low-float plays or momentum trades, this is something to watch. When an alert comes through - they can move fast🚀⁩

0 · Reply

CrnTrend May. 19 at 12:56 PM

$INZY

0 · Reply

itban_omair May. 19 at 4:25 AM

$INZY looks like ppl will be shorting this on Monday morning

1 · Reply

Market Cap	257.60M
Revenue (ttm)	0.00
Net Income (ttm)	-102.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.46

Volume	701,100
Avg Vol	2,498,570
Day's Range	N/A - N/A
Shares Out	64.56M
Stochastic %K	0%
Beta	2.29
Analysts	Sell
Price Target	$6.71